Among endogenous biomolecules and pathways characterized as effectors of cancer drug resistance, glucosylceramide synthase (GCS)-catalyzed ceramide glycosylation directly decreases cellular pro-apoptotic ceramide levels and increases anti-apoptotic glucosylceramide (GlcCer) levels [1,2]. The gene discussed is UGCG; the disease is cancer.